{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-009695","form_type":"8-K","ticker":"ENSC","cik":"0001716947","company_name":"Ensysce Biosciences, Inc.","filed_at":"2025-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.570758+00:00","generated_at":"2026-05-25T01:48:30.177841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Ensysce reports Q4 net loss $3.6M, cash $3.5M; signs PF614 commercial launch partner","bullets":["Cash $3.5M at Dec 2024 vs $4.2M Sept 2024 and $1.1M Dec 2023; 2024 net loss $8.0M vs $10.6M in 2023.","Entered strategic partnership with specialty manufacturer for commercial launch of PF614 and PF614-MPAR.","PF614-MPAR-102 interim data show overdose protection at 100 mg dose; study continues at higher doses.","FDA feedback on PF614 phase 3 design received; enrollment expected Q2 2025; NDA submission targeted for 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-009695","json":"https://secwatch.observer/filing/0001493152-25-009695.json","markdown":"https://secwatch.observer/filing/0001493152-25-009695.md","text":"https://secwatch.observer/filing/0001493152-25-009695.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/0001493152-25-009695-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716947/000149315225009695/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T01:48:30.177841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}